American Diabetes Association and GlaxoSmithKline Announce Creation of Research Award

Primary tabs

American Diabetes Association and GlaxoSmithKline Announce Creation of Research Award

Research funding of $1.5 million will explore the microbiome and metabolic changes in obesity and diabetes
tweet me:
.@GSKUS funds $1.5M award with @AmDiabetesAssn for research grants on nutrition, the microbiome, and obesity
Monday, June 11, 2012 - 12:00pm

CONTENT: Press Release

(3BL Media) June 11, 2012 -The American Diabetes Association is pleased to announce the creation of The American Diabetes Association and GlaxoSmithKline Research Award. The $1.5 million award, made possible through GlaxoSmithKline, will support a series of research grants focusing on the relationship between nutrition, the microbiome and metabolic pathologies, like obesity and diabetes.

As a leader in the fight to Stop Diabetes®, the American Diabetes Association supports research aimed at better understanding how we can prevent, treat and cure diabetes, and we are thrilled to join with GlaxoSmithKline,” said Vivian Fonseca, MD, President, Medicine & Science, American Diabetes Association. “The American Diabetes Association and GlaxoSmithKline Research Award will help increase our knowledge of the metabolic changes that affect both glucose and cardiometabolic risk factors, and provide the insight we need to better understand the connection between diabetes and obesity.” 

The American Diabetes Association and GlaxoSmithKline Research Award will support research aimed at understanding the impact of changes in diet, lifestyle and/or therapeutics on microbiome composition and function; and the mechanistic pathways through which microbiome composition and function may impact host metabolic function. This research will provide a better understanding of the role of the microbiome in patients who are obese and/or have diabetes. The microbiome has long been recognized for its role in the gastrointestinal tract, but more needs to be done to evaluate the emerging regulatory role it plays in metabolism.

“Diet is a fundamental cornerstone of the management of diabetes and we still don’t fully understand the effect of diet and the microbiome on glucose and other metabolic parameters,” said Murray Stewart, Therapy Area Head for Metabolism Research and Development, GlaxoSmithKline. “GlaxoSmithKline is delighted to work with the American Diabetes Association and hopes this research will advance our understanding in this area and improve the lives of people with diabetes.”

The grants will be three-year awards, starting in 2013. For more information, please visit

The American Diabetes Association is leading the fight to Stop Diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit Information from both these sources is available in Englishand Spanish.

About GlaxoSmithKline

GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information go to, follow us on or visit our blog( 
GSK on or visit the GSK blog: (    


Keywords: Health & Healthcare | American Diabetes Association | GlaxoSmithKline | Research | diabetes | metabolic pathologies | microbiome | nutrition | obesity

CONTENT: Press Release